Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Methionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.49 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | GCLC | P48506 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL8463168 | 1.00 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Racemethionine SCHEMBL23930380 | 0.98 | BHMT (0.50) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Methionine SCHEMBL291986 | 0.98 | BHMT (0.50) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Racemethionine SCHEMBL291985 | 0.98 | BHMT (0.50) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Methionine SCHEMBL28261828 | 0.96 | BHMT (0.46) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Methionine SCHEMBL9192308 | 0.96 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Racemethionine SCHEMBL29172847 | 0.96 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Racemethionine SCHEMBL9192305 | 0.96 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Racemethionine SCHEMBL9190291 | 0.96 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 | |
| Methionine SCHEMBL28118990 | 0.96 | BHMT (0.49) | BHMTBHMT2PMP22RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112715764-A | Antibiotic-free piglet compound feed and preparation method thereof | 天津市现代天骄农业科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| US-6787134-B1 | Methods for preventing/remedying mastitis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-07 | — | — | US | claimed |
| EP-1043028-A1 | METHOD FOR PREVENTING/REMEDYING MASTITIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-11 | — | — | EP | claimed |
| WO-2000000166-A2 | IMPROVED ORAL COMPOSITIONS FOR CONTROL AND PREVENTION OF TARTAR, ORAL MALODOR, PLAQUE AND GINGIVITIS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | claimed |
| US-20240325329-A1 | Livestock Feed | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-10-03 | — | — | US | disclosed |
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240180857-A1 | Livestock Feed | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240139124-A1 | Livestock Feed | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-05-02 | — | — | US | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11957768-B2 | Wet wiper articles and methods for cleaning removable dental appliances | Oral Health Technologies, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240114926-A1 | Livestock Feed | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2000000166-A2 | IMPROVED ORAL COMPOSITIONS FOR CONTROL AND PREVENTION OF TARTAR, ORAL MALODOR, PLAQUE AND GINGIVITIS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1998011867-A1 | ORAL COMPOSITIONS CONTAINING A ZINC COMPOUND | WARNER-LAMBERT COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0556498-B1 | L-form 1:1 metal methionine complexes | ZINPRO CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5278329-A | Methylsulfidyl-3-aminopropanyl carboxylates | ZINPRO CORPORATION (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0556498-A2 | L-form 1:1 metal methionine complexes | ZINPRO CORPORATION (US) | 1993-08-25 | — | — | EP | disclosed |
| US-4039681-A | ZINC METHIONINE COMPLEX FOR ACNE TREATMENT | ZINPRO CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-4021569-A | Method of nutritional supplementation for zinc and methionine by ingesting 1:1 zinc methionine complexes | ZINPRO CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
| US-3941818-A | 1:1 Zinc methionine complexes | ZINPRO CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | BHMT 3077/4885BHMT2 1231/4885PMP22 3179/4885 |
| US-20240139124-A1 | Livestock Feed | PIGS, MAFG, SLC6A12 | BHMT 1453/4885BHMT2 1297/4885PMP22 4683/4885 |
| US-20240180857-A1 | Livestock Feed | BLVRB, LRBA, MAFG | BHMT 883/4885BHMT2 1374/4885PMP22 4335/4885 |
| US-20240325329-A1 | Livestock Feed | SLC6A5, AADAT, AGXT | BHMT 257/4885BHMT2 176/4885PMP22 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.